AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
KKR to Sell Headlands Research to Thomas H. Lee Partners for Undisclosed Value
ByAinvest
Thursday, Aug 14, 2025 2:06 pm ET1min read
Thomas H. Lee Partners has agreed to acquire Headlands Research from KKR for an undisclosed value in a deal expected to close in 2025. A cash consideration will be paid, with an undisclosed value for common equity. McDermott Will & Schulte LLP and Paul Weiss acted as legal advisors for Thomas H. Lee Partners, while Jefferies Financial Group and Edgemont Capital Partners served as financial advisors. Houlihan Lokey and Kirkland & Ellis acted as advisors for KKR.
Thomas H. Lee Partners (THL) has entered into a definitive agreement to acquire Headlands Research, a leading multinational network of clinical trial sites, from KKR. The deal, expected to close in 2025, will see THL invest in Headlands through its flagship Fund IX. Financial terms were not disclosed.Headlands Research operates an integrated network of clinical trial sites across North America, conducting trials in therapeutic areas including central nervous system disorders, vaccines, and metabolic diseases. The company was founded by KKR in 2018 through its Health Care Strategic Growth Fund. The acquisition aims to fuel Headlands’ continued expansion, enhance its technology infrastructure, and strengthen its ability to deliver clinical trial data for pharmaceutical and biotech sponsors.
THL has been active in pharmaceutical services for over 25 years, with previous investments including Fisher Scientific, PCI Pharma Services, and Syneos Health. The firm has a strong track record of investing in middle-market growth companies, particularly within the healthcare sector.
The transaction will be advised by McDermott Will & Schulte LLP and Paul Weiss as legal advisors for THL, with Jefferies Financial Group and Edgemont Capital Partners serving as financial advisors. KKR and Headlands were advised by Houlihan Lokey as financial advisor and Kirkland & Ellis as legal advisor.
References:
[1] https://www.businesswire.com/news/home/20250814383571/en/THL-Announces-Agreement-to-Acquire-Headlands-Research-from-KKR
[2] https://www.investing.com/news/company-news/thl-partners-to-acquire-clinical-trial-network-headlands-research-93CH-4192376
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet